A Systematic, Patient-Centered Approach to Managing Metastatic Gastric or GEJ Adenocarcinoma
Curriculum:
A Systematic, Patient-Centered Approach to Managing Metastatic Gastric or GEJ Adenocarcinoma
A Systematic, Patient-Centered Approach to Managing Metastatic Gastric or GEJ Adenocarcinoma
Credits:
1 AMA PRA Category 1 Credit(s) ™
1 AMA PRA Category 1 Credit(s) ™
Launch Date:
December 21, 2017
December 21, 2017
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Oncology clinicians including physicians, nurses, and PAs
Relevant Terms:
Metastatic gastric; gastroesophageal junction adenocarcinoma
Jaffer A. Ajani, MD
Jaffer A. Ajani, MD
Professor of Medicine, Department of Gastrointestinal Medical Oncology
University of Texas MD Anderson Cancer Center
Houston, TX
Bio
Jaffer A. Ajani, MD, is a professor of medicine and an internist at the University of Texas MD Anderson Cancer Center in Houston, TX, where he works in the department of gastrointestinal medical oncology.
After completing his undergraduate studies, Dr Ajani earned his medical degree from Government Medical College in Nagpur, India, where he completed a rotating internship and a residency in general surgery and orthopedics before continuing on to Pennsylvania State University for an internship and residency in family practice. Dr Ajani completed his internship and residency in internal medicine at Tulane University School of Medicine and was subsequently awarded a clinical fellowship in medical oncology at the MD Anderson Cancer Center. He remained at the center for an additional 2-year research fellowship in medical oncology.
Dr Ajani is the Chief Scientific Officer of the International Society of Gastrointestinal Cancer. He has chaired the National Comprehensive Cancer Network's Esophageal and Gastric Adenocarcinoma Guidelines committee for 20+ years. Previously, he served as chair of the medical oncology committee of the Radiation Therapy Oncology Group.
Dr Ajani is board certified in family medicine and internal medicine, as well as the medical oncology subspecialty. His primary research interest is gastrointestinal oncology. He has written more than 450 peer reviewed publications on the topic. He is the recipient of several NCI and DOD grants.
After completing his undergraduate studies, Dr Ajani earned his medical degree from Government Medical College in Nagpur, India, where he completed a rotating internship and a residency in general surgery and orthopedics before continuing on to Pennsylvania State University for an internship and residency in family practice. Dr Ajani completed his internship and residency in internal medicine at Tulane University School of Medicine and was subsequently awarded a clinical fellowship in medical oncology at the MD Anderson Cancer Center. He remained at the center for an additional 2-year research fellowship in medical oncology.
Dr Ajani is the Chief Scientific Officer of the International Society of Gastrointestinal Cancer. He has chaired the National Comprehensive Cancer Network's Esophageal and Gastric Adenocarcinoma Guidelines committee for 20+ years. Previously, he served as chair of the medical oncology committee of the Radiation Therapy Oncology Group.
Dr Ajani is board certified in family medicine and internal medicine, as well as the medical oncology subspecialty. His primary research interest is gastrointestinal oncology. He has written more than 450 peer reviewed publications on the topic. He is the recipient of several NCI and DOD grants.
| 1. | Summarize the pathogenesis and molecular pathways involved in the development and progression of gastric cancer | 2. | Evaluate the safety, efficacy, and quality of data for available and emerging targeted therapies for locally advanced or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma |
| 3. | Individualize and optimize treatment with sequencing and management of treatment-related adverse events for locally advanced or metastatic gastric and GEJ adenocarcinoma | 4. | Engage patients with locally advanced or metastatic gastric and GEJ adenocarcinoma in their care by implementing effective shared decision making (SDM) strategies |
| 1. | Summarize the pathogenesis and molecular pathways involved in the development and progression of gastric cancer |
| 2. | Evaluate the safety, efficacy, and quality of data for available and emerging targeted therapies for locally advanced or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma |
| 3. | Individualize and optimize treatment with sequencing and management of treatment-related adverse events for locally advanced or metastatic gastric and GEJ adenocarcinoma |
| 4. | Engage patients with locally advanced or metastatic gastric and GEJ adenocarcinoma in their care by implementing effective shared decision making (SDM) strategies |
CONTINUING EDUCATION INFORMATION
CE Credit provided by AKH Inc., Advancing Knowledge in HealthcarePhysicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
Nurses
AKH Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is awarded 1.0 Contact Hour.
Jointly provided by RMEI Medical Education, LLC and AKH Inc., Advancing Knowledge in Healthcare.
DISCLOSURE DECLARATION
It is the policy of RMEI Medical Education, LLC and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by RMEI and AKH Inc. prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc. planners and reviewers have no relevant financial relationships to disclose.
It is the policy of RMEI Medical Education, LLC and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by RMEI and AKH Inc. prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc. planners and reviewers have no relevant financial relationships to disclose.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
- Jaffer A. Ajani, MD, has affiliations with Bristol-Myers Squibb, Celgene, Genentech, Insys, Lilly, and Medscape (Consulting Fees), and Bristol-Myers Squibb and Delta-Fly (Contracted Research).
RMEI Medical Education, LLC
- Tania Dickson, MD, has no affiliations with commercial interests to disclose.
- Mindy Tanzola, PhD, has no affiliations with commercial interests to disclose.
- Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
- Jessica Hatch has no affiliations with commercial interests to disclose.
AKH Inc. Staff and Planners
Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner: has no affiliations with commercial interests to disclose.
Patricia Brignoni, Sr. Project Manager: has no affiliations with commercial interests to disclose.
DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through the participant's misunderstanding of the content.
DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Estimated time to complete: 1 hour
Medium: Internet
Medium: Internet
FEE INFORMATION
There is no fee for this educational activity.
COMMERCIAL SUPPORT
This activity is supported by an educational grant from Lilly.
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians and PAs are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™ and nurses are entitled to receive up to 1.0 contact hour. A statement of credit will be available to print from your user history page. Users must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity post-test and evaluation.
Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.
| Supported Browsers: Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |
© 2007-2024 HealthCourse, Inc. All rights reserved.
